GC Biopharma Corp. (KRX:006280)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Manufacturing and Sales of Pharmaceuticals, Etc.			1.44T	1.48T	-	1.43T	1.32T
Manufacturing and Sales of Pharmaceuticals, Etc. Growth			-2.94%	-	-	8.58%	-
Diagnosis and Analysis of Samples, Etc.			213.76B	262.18B	-	99.64B	70.22B
Diagnosis and Analysis of Samples, Etc. Growth			-18.47%	-	-	41.89%	-
Other			18.50B	22.10B	-	19.33B	15.74B
Other Growth			-16.29%	-	-	22.82%	-
Consolidation Adjustment			-46.49B	-57.45B	-	-42.08B	-33.12B
Energy Storage Device Manufacturing and Sales			-	-	1.54T	-	-
Profit and Loss from Discontinued Operations			-	-	-	-2.67B	-12.59B
Total			1.63T	1.71T	1.54T	1.50T	1.36T
Total Growth			-4.95%	11.28%	2.24%	10.83%	1.67%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Overseas			272.87B	306.71B	39.46B	271.82B	229.31B
Overseas Growth			-11.03%	677.21%	-85.48%	18.54%	-2.40%
South Korea			1.40T	1.46T	9.50B	1.28T	1.17T
South Korea Growth			-4.23%	15297.99%	-99.26%	8.82%	3.59%
Consolidation			-46.49B	-57.45B	-	-42.08B	-33.12B
Discontinued Operations			-	-	-	-2.67B	-12.59B
Total			1.63T	1.71T	48.96B	1.50T	1.36T
Total Growth			-4.95%	3395.47%	-96.75%	10.83%	1.67%

Source: S&P Global Market Intelligence.